<DOC>
	<DOCNO>NCT00499590</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness bevasiranib give either every 8 week every 12 week initial pre-treatment 3 injection Lucentis® ( ranibizumab injection ) compare Lucentis® give every 4 week people wet AMD . Patients assigned random ( like toss coin ) receive one three treatment option 104 week .</brief_summary>
	<brief_title>Safety &amp; Efficacy Study Evaluating Combination Bevasiranib &amp; Lucentis Therapy Wet AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Patients must age 50 year old 2 . Patients must predominantly classic , minimally classic occult classic lesion secondary Age Related Macular Degeneration . 3 . The study eye must ETDRS best correct visual acuity 69 24 letter ( 20/40 20/320 Snellen equivalent ) . 4 . Patients must willing able return schedule monthly followup visit twoyears . 1 . Prior pharmacologic treatment AMD study ( patient previously receive Avastin®/Lucentis® , Macugen® , antiVEGF agent , steroid treatment , PDT , radiation treatment , experimental therapy AMD study eye ) 2 . Any intraocular surgery study eye within 12 week screen 3 . Previous posterior vitrectomy study eye 4 . Advanced glaucoma intraocular pressure 22 mm Hg study eye despite treatment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>AMD</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>bevasiranib</keyword>
	<keyword>COBALT study</keyword>
	<keyword>age relate macular degeneration</keyword>
	<keyword>wet AMD</keyword>
	<keyword>wet age relate macular degeneration</keyword>
</DOC>